Bristol Myers Squibb (CELG-RI) Common Equity (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Common Equity of $22.3 billion for Q2 2026, down 51.62% year-over-year from $46.1 billion in Q2 2025, and down 51.87% quarter-over-quarter from $46.4 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Common Equity (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Common Equity for 18 consecutive years, with $22.3 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Common Equity fell 51.62% year-over-year to $22.3 billion; the TTM figure through Jun 2026 stood at $22.3 billion (down 51.62% YoY), while the FY2025 annual figure was $18.5 billion, down 59.79% from the prior year.
- Common Equity slipped to $22.3 billion in Q2 2026 per CELG-RI's latest filing, from $46.4 billion in the prior quarter.
- Across five years, Common Equity topped out at $46.4 billion in Q1 2026 and bottomed at $18.5 billion in Q4 2025.
- Historically, Common Equity has averaged $41.1 billion across 5 years, with a median of $45.2 billion in 2022.
- Annual changes were most pronounced in 2023 — Common Equity grew 3.16% — and 2025, when it slumped 59.79%.
- Bristol Myers Squibb's Common Equity stood at $45.2 billion in 2022, then increased by 1.15% to $45.7 billion in 2023, then increased by 0.74% to $46.0 billion in 2024, then plunged by 59.79% to $18.5 billion in 2025, then advanced by 20.6% to $22.3 billion in 2026.
- Business Quant data shows CELG-RI's Common Equity at $22.3 billion in Q2 2026, $46.4 billion in Q1 2026, and $18.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.37 Bn | 633.61 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 471.07 Bn | 464.50 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 378.82 Bn | 371.68 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 259.11 Bn | 254.21 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 237.62 Bn | 223.63 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 183.34 Bn | 180.16 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 161.05 Bn | 149.36 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 106.03 Bn | 101.87 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 22.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.32 Bn |
| Mar 31, 2026 | 20.10 Bn |
| Dec 31, 2025 | 18.51 Bn |
| Sep 30, 2025 | 292.00 Mn |
| Jun 30, 2025 | 292.00 Mn |
| Mar 31, 2025 | -1.42 Bn |
| Dec 31, 2024 | 14.91 Bn |
| Sep 30, 2024 | 16.10 Bn |
| Jun 30, 2024 | 54.00 Mn |
| Mar 31, 2024 | 15.64 Bn |
| Dec 31, 2023 | 55.00 Mn |
| Sep 30, 2023 | 44.85 Bn |
| Jun 30, 2023 | 45.30 Bn |
| Mar 31, 2023 | 26.57 Bn |
| Dec 31, 2022 | -1.28 Bn |
| Sep 30, 2022 | 292.00 Mn |
| Jun 30, 2022 | 24.22 Bn |
| Mar 31, 2022 | 65.00 Mn |
| Dec 31, 2021 | 44.36 Bn |
| Sep 30, 2021 | -1.42 Bn |